Boston Scientific's Revenue in the fiscal year 2025 $ 20,075.00 millions
Boston Scientific's Revenue in the fiscal year 2024 $ 16,747.00 millions
Boston Scientific's Revenue in the fiscal year 2023 $ 14,241.00 millions
Boston Scientific's Revenue in the fiscal year 2022 $ 12,683.00 millions
Boston Scientific's Revenue in the fiscal year 2021 $ 11,888.00 millions
BSX Revenue third quarter 2026 Y/Y Growth Comment
Boston Scientific Corporation reported Revenue growth of 1.44% year on year in the third quarter 2026, to $ 5,138.00 millions, this is lower than Boston Scientific Corporation's recent average Revenue growth of 8.27%.
Looking into third quarter 2026 results within Medical Equipment & Supplies industry 129 other companies have achieved higher Revenue growth. While Boston Scientific Corporation' s Revenue increase of 1.44% ranks overall at the positon no. 2721 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Boston Scientific's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
99.41 %
2.72 %
-52.89 %
(Dec 31 2019)
BSX's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Boston Scientific Corporation disclosed decline in Revenue from the second quarter by -5.59% to $ 5,138.00 millions, from $ 5,442.00 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.
Within Medical Equipment & Supplies industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Boston Scientific's Revenue growth quarter on quarter, overall rank is 2590.
In the III. Quarter 2026 Boston Scientific Corporation disclosed decline in Revenue from the second quarter by -5.59% to $ 5,138.00 millions, from $ 5,442.00 millions achived in the previous reporting period.
Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.
Within Medical Equipment & Supplies industry 97 other companies have achieved higher Revenue quarter on quarter growth. While Boston Scientific's Revenue growth quarter on quarter, overall rank is 2590.
Boston Scientific's 12 Months Revenue Growth Year on Year
Assuming the Boston Scientific's fiscal year would have ended in Sep 30 2026, Boston Scientific would have reprted above average annual Revenue improvement of 8.89% year on year, of $ 21,070 millions. This marks a slow-down of the companys growth trends and from the 13.53% rise in Jun 30 2026.
In the Healthcare sector 163 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1003, from total ranking in previous quarter at 1005.
Assuming the Boston Scientific's fiscal year would have ended in Sep 30 2026, Boston Scientific would have reprted above average annual Revenue improvement of 8.89% year on year, of $ 21,070 millions. This marks a slow-down of the companys growth trends and from the 13.53% rise in Jun 30 2026.
In the Healthcare sector 163 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1003, from total ranking in previous quarter at 1005.
About Boston Scientific Revenue Growth Rates (BSX), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
2.27%